IC patients, especially transplant recipients, developed lower immunogenicity with two-dose of COVID-19 mRNA vaccines. Among patients with IC, those with autoimmune conditions and solid organ malignancies are mostly benefited from COVID-19 vaccination. Findings from this meta-analysis could aid healthcare policymakers in making decisions regarding the importance of the booster dose or more strict personal protections in the IC patients.
No takes yet. Share an insight, caveat, or question.
Nejad et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: